Metformin in early breast cancer: A prospective window of opportunity neoadjuvant study

Breast Cancer Research and Treatment

Volumn 135, Issue 3, 2012, Pages 821-830

  Niraula, Saroj ^a   Dowling, Ryan J O ^b   Ennis, Marguerite ^c   Chang, Martin C ^a,d   Done, Susan J ^b,d   Hood, Nicky ^a   Escallon, Jaime ^a,e   Leong, Wey Liang ^b,e   McCready, David R ^a,e   Reedijk, Michael ^b,e   Stambolic, Vuk ^b   Goodwin, Pamela J ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c Applied Statistician   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Breast cancer; Insulin; Ki67; Metformin; Neoadjuvant; TUNEL

Indexed keywords

C REACTIVE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLUCOSE; INSULIN; KI 67 ANTIGEN; LEPTIN; METFORMIN; PROGESTERONE RECEPTOR;

ABDOMINAL DISTENSION; ADJUVANT THERAPY; ADULT; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLOATING; BODY MASS; BODY WEIGHT; BREAST CANCER; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM ULCER; DIZZINESS; DRUG ERUPTION; DRUG TOLERABILITY; DYSPEPSIA; EARLY CANCER; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEARTBURN; HUMAN; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LYMPH NODE METASTASIS; METABOLIC ACIDOSIS; NAUSEA; NICK END LABELING; PREOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SYMPTOM; TASTE DISORDER; TREATMENT DURATION; TUMOR BIOPSY; VOMITING;

APOPTOSIS; BODY MASS INDEX; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; KI-67 ANTIGEN; METFORMIN; MIDDLE AGED; NEOADJUVANT THERAPY; PREOPERATIVE CARE; QUALITY OF LIFE;

EID: 84866538325     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2223-1     Document Type: Review

References (37)

1. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S (2010) Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 3:1451-1461
2. Zhang ZJ, Zheng ZJ, Kan H, Song Y, Cui W, Zhao G, Kip KE (2011) Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care 34:2323-2328
3. Chlebowski RT, McTiernan A, Wactawski-Wende J, Manson JE, Aragaki AK, Rohan T, Ipp E, Kaklamani VG, Vitolins M, Wallace R, Gunter M, Phillips LS, Strickler H, Margolis K, Euhus DM (2012) Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol 30:2844-2852
4. Col NF, Ochs L, Springmann V, Aragaki AK, Chlebowski RT (2012) Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat. doi: 10.1007/s10549-012-2170-x
5. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297-3302
6. Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG (2008) Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer 8:501-505
7. Duggan C, Irwin ML, Xiao L, Henderson KD, Smith AW, Baumgartner RN, Baumgartner KB, Bernstein L, Ballard-Barbash R, McTiernan A (2011) Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol 29:32-39
8. Emaus A, Veierod MB, Tretli S, Finstad SE, Selmer R, Furberg A-S, Bernstein L, Schlichting E, Thune I (2010) Metabolic profile, physical activity, and mortality in breast cancer patients. Breast Cancer Res Treat 121:651-660
9. Irwin ML, Duggan C, Wang CY, Smith AW, McTiernan A, Baumgartner RN, Baumgartner KB, Bernstein L, Ballard-Barbash R (2011) Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. J Clin Oncol 29:47-53
10. Erickson K, Patterson RE, Flatt SW, Natarajan L, Parker BA, Heath DD, Laughlin GA, Saquib N, Rock CL, Pierce JP (2011) Clinically defined type 2 diabetes mellitus and prognosis in earlystage breast cancer. J Clin Oncol 29:54-60
11. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Taylor SK, Hood N (2012) Insulin-and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. J Clin Oncol 30:164-171
12. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 230:586-623
13. Mulligan AM, O'Malley FP, Ennis M, Fantus IG, Goodwin PJ (2007) Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Res Treat 106:39-47 (Pubitemid 47498088)
14. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269-10273 (Pubitemid 44799743)
15. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N (2007) Metformin inhibits mammalian target of rapamycindependent translation initiation in breast cancer cells. Cancer Res 67:10804-10812 (Pubitemid 350145909)
16. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003. http://ctep.cancer.gov. Publish Date: 9 August 2006
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetology 28:412-419 (Pubitemid 15018832)
18. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795
19. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145 (Pubitemid 350003059)
20. Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359-377
21. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403-410
22. Dowsett M, Nielsen TO, A'Hern R et al (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103:1656-1664
23. Dowsett M, Dixon JM, Horgan K, Salter J, Hills M, Harvey E (2000) Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer. Clin Cancer Res 6:2260-2267 (Pubitemid 30399192)
24. Niraula S, Stambolic V, Dowling R, Ennis M, Chang M, Done S, Hallak S, Hood N, Leong W, Escallon J, Goodwin PJ (2010) Clinical and biologic effects of metformin in early stage breast cancer. Cancer Res 70(24 Suppl):104s
25. Frassoldati A, Maur M, Guarneri V, Nicolini M, Conte PF (2005) Predictive value of biologic parameters for primary chemotherapy in operable breast cancer. Clin Breast Cancer 6:315-324 (Pubitemid 41715692)
26. Archer CD, Parton M, Smith IE et al (2003) Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer 89:1035-1041 (Pubitemid 37239208)
27. Tomic T, Botton T, Cerezo M et al (2011) Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis 2:e199
28. Yasmeen A, Beauchamp MC, Piura E, Segal E, Pollak M, Gotlieb WH (2011) Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecol Oncol 121:492-498
29. Malki A, Youssef A (2011) Antidiabetic drug metformin induces apoptosis in human MCF breast cancer via targeting ERK signaling. Oncol Res 19:275-285
30. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD (2009) Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8:2031-2040
31. Wang LW, Li ZS, Zou DW, Jin ZD, Gao J, Xu GM (2008) Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol 14:7192-7198
32. Li M, Liu J, Hu WL, Jia CH, Li HY, Wen ZH, Zou ZP, Bai XC, Luo SQ (2011) Effect of metformin on apoptosis of renal cell carcinoma cells in vitro and its mechanisms. Nan Fang Yi Ke Da Xue Xue Bao 31:1504-1508
33. Zakikhani M, Blouin MJ, Piura E, Pollak MN (2010) Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 123:271-279
34. Hadad S, Iwamoto T, Jordan L et al (2011) Evidence for biological effects of metformin in operable breast cancer: a preoperative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 128:783-794
35. Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, Gennari A, Trabacca MS, Galimberti V, Veronesi P, Johansson H, Aristarco V, Bassi F, Luini A, Lazzeroni M, Varricchio C, Viale G, Bruzzi P, Decensi A (2012) Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 30:2593-2600
36. Ellis PA, Smith IE, Detre S, Burton SA, Salter J, A'Hern R, Walsh G, Johnston SR, Dowsett M (1998) Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 48:107-116 (Pubitemid 28156355)
37. Romero Q, Bendahl PO, Klintman M, Loman N, Ingvar C, Ryden L, Rose C, Grabau D, Borgquist S (2011) Ki67 proliferation in core biopsies versus surgical samples-a model for neo-adjuvant breast cancer studies. BMC Cancer 11:341